Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year

Inclusion criteria: * Moderate and severe plaque-type psoriasis diagnosed for at least 6 months. * Severity of psoriasis disease meeting all of the following three criteria: * Psoriasis Area and Severity Index (PASI) score of 12 or greater, * Investigator's Global Assessment (IGA) score of 3 or greater, * Total body surface area (BSA) affected of 10% or greater. * Inadequate control by prior use of topical treatment, phototherapy and/or systemic therapy. Exclusion criteria: * Current forms of psoriasis other than chronic plaque-type psoriasis (for example, pustular, erythrodermic, guttate). * Current drug-induced psoriasis. * Previous use of secukinumab or any drug that targets IL-17 or IL-17 receptor. * Significant medical problems such as uncontrolled hypertension, congestive heart failure or a condition that significantly immunocompromises the subject. * Hematological abnormalities. * History of an ongoing, chronic or recurrent infectious disease, or evidence of untreated tuberculosis. * History of lymphoproliferative disease or history of malignancy of any organ system within the past 5 years. * Pregnant or nursing (lactating) women. * Subjects not willing to limit UV light exposure during the study Other protocol-defined inclusion/exclusion criteria may apply.